Search Results
Sep 25, 2025, 14:01 ET FACILITRON UNIVERSITY 5 ANNOUNCES ADMIRAL JOHN SHEA AS FEATURED SPEAKER, ALONG WITH POWERFUL SESSIONS ON GOVERNANCE, EQUITY, AND THE FUTURE OF SCHOOL FACILITIES
Rentals: Facilities as Strategic AssetsFireside chat with industry leaders Al Grazioli, Gene Fuller, and Mark Borrison on how facilities can be leveraged for housing, sustainability, long-term planning,
More news about: Facilitron
Sep 25, 2025, 13:25 ET New Partnership Brings Next-Generation Cell Isolation Solutions to Researchers Advancing Cell and Gene Therapy Development
separation technology, announced today a distribution partnership to expand access to Akadeum's next-generation cell isolation technology for cell and gene therapy development. Under the agreement, Cayman will distribute Akadeum's portfolio of buoyant microbubble cell isolation kits, integrating
More news about: Cayman Chemical
Sep 25, 2025, 10:30 ET Huntington's Disease Foundation - New Name, Same Mission
individuals spanning 10 generations. In 1983, HDF formed the Gene Hunters, a collaboration of 100 international scientists who, a decade later, used the clinical information from Venezuela to identify the HD gene - a landmark achievement that revolutionized Huntington's
More news about: Huntington's Disease Foundation
Sep 25, 2025, 09:15 ET Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
unprecedented demand for precision healthcare solutions, with population projections showing nearly one in four Americans will be over 65 by 2060[1]. Gene therapy approvals continue accelerating as the FDA recently approved breakthrough treatments targeting rare diseases[2], while AI-powered
More news about: USA News Group
Sep 25, 2025, 09:03 ET Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson's Disease
for Regenerative Medicine (CIRM), a state of California agency that supports regenerative medicine, stem cell, and gene therapy research, which enabled Cohorts 1 and 2.
More news about: Aspen Neuroscience, Inc.
Sep 25, 2025, 09:00 ET YouthBio Therapeutics Announces Positive FDA INTERACT Feedback for YB002, Establishing Clear Path to Clinic for First-in-Class Alzheimer's Gene Therapy
"Their detailed feedback allows us to focus our resources effectively and build the most robust IND package possible." YB002 is a first-in-class gene therapy designed to safely and transiently express Yamanaka factors in the brain — a process known as partial reprogramming. Built on Nobel Prize-winning
More news about: YouthBio Therapeutics Inc.
Sep 25, 2025, 08:05 ET INOVIO to Participate in Upcoming Scientific Conferences
Medicine: European Society of Gene and Cell Therapy CongressSeville, ESDate: October 7-10Poster Title: Employment of the CELLECTRA® in vivo gene delivery platform in a first in human (FIH) DNA
More news about: INOVIO Pharmaceuticals, Inc.
Sep 25, 2025, 08:00 ET Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London
world's highest market value CAR-T company, will share the story of Legend's success. Latest Progress and Future Outlook in Gene Therapy and mRNA Gene therapy and mRNA technologies have moved from promise to practice, delivering clinical milestones in both rare diseases and broader
More news about: GenScript Biotech Corporation
Sep 25, 2025, 08:00 ET Verismo Therapeutics Announces Partnership with Miltenyi Biotec to Support Advancing Clinical Programs
is an important step in preparation for Phase 2 and beyond, including use in commercial applications. Miltenyi Bioindustry is a leader in translating gene-edited cell therapy products into the clinic, including design, construction, and production of lentiviral vectors, from research through GMP manufacturing.
More news about: Verismo Therapeutics
Sep 25, 2025, 08:00 ET National Ataxia Foundation Partners with Biogen to Bring Bill Nye "the Science Guy" Back To the Lab With New Series About Friedreich Ataxia
rare, it is also one of the most commonly inherited genetic forms of ataxia.4 FA is caused by an abnormality of the frataxin (FXN) gene and levels of FXN in the spinal cord and brain are much lower than normal in people who have FA.5 Since FA is rare and symptoms can resemble
More news about: National Ataxia Foundation
Sep 25, 2025, 06:30 ET AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer
tolerability, pharmacodynamic (PD) markers, and pharmacokinetics (PK) of AP-101 in patients with sporadic ALS and patients with mutations in the SOD1 gene. About AL-S Pharma AGAL-S Pharma is a Swiss-based single-asset company founded and co-owned by Neurimmune and TVM Capital Life
More news about: AL-S Pharma AG
Sep 24, 2025, 16:51 ET Study Reveals How Tick-Borne Encephalitis Virus Enters Cells
targeted. Using a human cell line, they amassed a "library" of thousands of cell variants in which a different gene had been deleted; the variants were then exposed to TBEV. Only cell types lacking a gene necessary for TBEV infection should survive virus exposure. Unmasking the Culprit As
More news about: Albert Einstein College of Medicine
Sep 24, 2025, 14:13 ET Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hamlet BioPharma AB
Sep 24, 2025, 14:06 ET Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy,
More news about: Hamlet BioPharma AB
Sep 24, 2025, 11:13 ET Children's Hospital of Philadelphia Researchers Find Combination of Diet and Medication Reprograms Fatal Childhood Tumors
and his team used a preclinical model to mimic MYCN-driven neuroblastoma, directly addressing the strong association between extra MYCN gene copies and aggressive neuroblastoma with poor prognosis. Animal models with tumors were divided into groups: one fed a normal diet and the other lacking
More news about: Children's Hospital of Philadelphia
Sep 24, 2025, 10:59 ET ENCELTO Now Available Through OCLI Vision to Address Rare Retinal Disease, Announces Spectrum Vision Partners
practice managed by Spectrum Vision Partners, made medical history on September 22, 2025, by performing the first ENCELTO gene therapy procedure in the Northeast United States. This landmark achievement marked only the second commercial implantation
More news about: Spectrum Vision Partners
Sep 24, 2025, 10:00 ET The RI Life Science Hub Announces Foundational Members of Ocean State Labs, the State's First Life Science Incubator
Pax Therapeutics, advancing gene-delivery technologies to optimize healing of tendon and ligament injuries.
More news about: Rhode Island Life Science Hub
Sep 24, 2025, 09:31 ET ResVita Bio Announces Positive FDA Pre-IND Meeting, Advancing RVB-003 Toward IND Filing for Netherton Syndrome in Early 2026
Netherton Syndrome (NS) is caused by mutations in the SPINK5 gene, leading to uncontrolled protease activity, chronic skin inflammation, and life-threatening barrier defects. Patients face high morbidity and mortality,
More news about: ResVita Bio
Sep 24, 2025, 09:00 ET Hood College Receives NSF Grant for Biotechnology Training Program
the bioscience industry," said Rana Khan, inaugural director of BREC. "Focused on cutting-edge technologies in gene therapy and biomanufacturing, this funding will provide hands-on training and paid internships for our students while strengthening industry partnerships
More news about: Hood College
Sep 24, 2025, 02:45 ET New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
sustained efficacy and a consistent safety profile for people with RMS," said Norman Putzki, M.D., Ph.D., Global Head Development, Neuroscience & Gene Therapy, Novartis. "These findings reinforce Kesimpta's position as a therapy that empowers patients to take early control of their disease."
More news about: Novartis Pharmaceuticals Corporation
Sep 23, 2025, 21:19 ET Mindray stellt auf der ISUOG „Project 2030" vor und schreibt Zukunft des Ultraschalls in der Frauenheilkunde neu
100 Artikeln – das ist die beeindruckende Bilanz des „Project 2025". Von nun an wird Mindray das „Project 2030" weiter umsetzen. Gene Liang, General Manager, Medical Imaging von Mindray, betonte: „Unser Ziel ist es, kontinuierlich zur Entwicklung einer Ultraschall-Grundausbildung
More news about: Mindray
Sep 23, 2025, 19:10 ET Mindray dévoile le Projet 2030 et réécrit l'avenir de l'échographie pour la santé des femmes à l'ISUOG
100 articles : telles sont les empreintes du Projet 2025. À l'avenir, Mindray continuera à mettre en œuvre le Projet 2030. Gene Liang, directeur général de l'imagerie médicale chez Mindray, a souligné : « Nous souhaitons contribuer sans cesse au développement de l'enseignement
More news about: Mindray
Sep 23, 2025, 12:08 ET LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly
("Remedium"), has entered into a multi-target research and development collaboration with Eli Lilly and Company ("Lilly") focused on advancing innovative gene therapies for Type 2 diabetes and obesity.
More news about: LifeSpan Vision Ventures
Sep 23, 2025, 12:06 ET Partillion's Nanovials Power Breakthrough Cell-Cell Interaction Mapping, Driving Call for Billion Cell × Cell Project
interaction-induced gene expression of single-cell pairs. "Current tools tell us what a cell is or where it resides, but not how it responds when it meets another cell. With Cell-Cell Seq, we finally capture how cells change each other over time by directly measuring the gene expression programs triggered
More news about: Partillion Bioscience
Sep 23, 2025, 11:39 ET LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly
("Remedium"), has entered into a multi-target research and development collaboration with Eli Lilly and Company ("Lilly") focused on advancing innovative gene therapies for Type 2 diabetes and obesity.
More news about: LifeSpan Vision Ventures